Objective: To examine the expressive level of enhancer of zesle homolog 2 (EZH2) and phosphatase and tension homolog (PTEN), and to explore its clinicopathological significance in benign and malignant lesion of gallbladder.
Methods: EnVision immunohistochemical method was used to detect the expressive levels of EZH2 and PTEN in routinely paraffin-embedded sections in the resected specimens of gallbladder adenocarcinoma (n = 108), peritumoral tissues (n = 46), adenomatous polyp(n = 15), and chronic cholecystitis (n = 35).
Results: The positive rate of EZH2 was significantly higher in gallbladder adenocarcinoma than that in peritumoral tissues (chi(2) = 24.49, P < 0.01), adenomatous polyp(chi(2) = 11.68, P < 0.01), and chronic cholecystitis (chi(2) = 31.62, P < 0.01). The benign lesions in the positive cases of EZH2 and (or) the negative ones of PTEN showed the moderately- or severely- atypical hyperplasia of gallbladder epithelium. The positive rate of PTEN was significantly lower in gallbladder adenocarcinoma than that in peritumoral tissues(n = 20.20, P < 0.01), adenomatous polyp(chi(2)=10.81, P<0.01), and chronic cholecystitis (n = 29.83, P < 0.01).The positive rates of EZH2 were significantly lower in the highly-differentiated adenocarcinoma, the maximal diameter of mass < 2 cm, non-metastasis of lymphnodes, and non-infiltration of regional tissues than those in the moderately or low-differentiated adenocarcinoma, the maximal diameter > or = 2 cm, metastasis of lymphnode, and infiltration of regional tissues (P < 0.05 or P < 0.01). High inconsistency was found between the expression of EZH2 and PTEN in gallbladder adenocarcinoma (P < 0.05).
Conclusion: Expression of EZH2 and/or PTEN might be important biological markers in the carcinogenesis, progression, biological behaviors and prognosis of gallbladder adenocarcinoma.